Media OutReach
Johnson & Johnson launches The 3rd Opinion in Asia Pacific: a new term to elevate the patient voice in the lung cancer treatment journey
- Newly published research shows up to 77% of patients in Asia Pacific trust and rely on their physicians to decide their treatment for them despite 69% of physicians encouraging patients to engage in shared decision making1.
- A new term, coined The 3rd Opinion, is designed to spark a social movement that empowers patients to recognize their vital role in shared decision-making, in a region that is disproportionately impacted by lung cancer2.
SINGAPORE –
According to newly published data on NSCLC patient preferences in Future Oncology, up to 77% of patients in Asia Pacific trust and rely on their physicians to decide their treatment for them despite 69% of physicians encouraging patients to engage in shared decision making[1]. Cultural norms around stigma, not questioning authority, and limited understanding of the disease can often be major barriers causing patients not to voice concerns or ask questions, even when healthcare professionals actively encourage their input.
“Being diagnosed with lung cancer is overwhelming. It’s natural for patients to seek clarity, often by pursuing a second opinion, to better understand their condition and treatment options. However, patients often hesitate to express their concerns and treatment goals, causing them to be overlooked in the decision-making process. By creating space for the patient’s own opinion, The 3rd Opinion, creates a new way of thinking about lung cancer treatment and empowers patients to find their voice,” said Anthony Elgamal, Vice President of Oncology, Johnson & Johnson Innovative Medicine Asia Pacific.
Lung cancer has the highest incidence and mortality rate of all cancers worldwide, with more than 2.5 million people diagnosed every year, and Asia makes up 63% of all patients[2]. Up to 85% of lung cancers are non-small cell lung cancer (NSCLC) and Asians are more prone to certain genetic mutations than the rest of the world. One of the most prevalent is a mutation known as EGFR where 30-40% of all NSCLC diagnoses are in Asia, compared to 10-15% in the United States and Europe[3][4][5]. Often being diagnosed at a late stage, less than 20% of people with these genetic mutations survive beyond five years[6], and up to 40% never get the chance to receive a subsequent therapy after first-line treatment.[7][8][9]
“With the disproportionately high prevalence of certain NSCLC mutations in Asia Pacific, we need to think differently about how we treat patients and what more we can achieve with the first treatment. Treatment options have become increasingly complex and clinical decision making should comprehensively consider disease characteristics, patient treatment goals and values, and aim for an individualized balance between survival, longer lasting disease control and side effects. When shared decision making includes all available options, the final decision can be made collaboratively,” said Prof James Chih-Hsin Yang, Director of National Taiwan University Cancer Center and key advocate for The 3rd Opinion initiative.
Mark Brooke, Chief Executive Officer of Lung Foundation Australia, co-author of the Future Oncology publication and an advocate of The 3rd Opinion agreed, “The physician and patient dynamic is one of trust, but we cannot rely on that alone. The consequence is a potential disconnect between the patient and their healthcare professional around treatment preferences and personal goals. For patients, they often want more time above all else – to witness life’s milestones, more moments with loved ones, and more opportunities to simply live. Patients need to be equipped with adequate disease and treatment information, so they can communicate what matters most to them”.
The 3rd Opinion will be launched across multiple markets with educational resources, including a Lung Cancer Book of Answers in China, a patient empowerment video and various shared decision making tools across Asia Pacific to spark a social movement that encourages patients to confidently articulate their personal goals for treatment. The creation of a neologism, like The 3rd Opinion, ensures shared decision making becomes accepted into clinical practice and in turn fosters an environment where the doctor’s expertise and the patient goals come together to design the best treatment plan.
Hashtag: #Johnson&Johnson
The issuer is solely responsible for the content of this announcement.
About The 3rd Opinion
“The 3rd Opinion”, the patients own opinion, is a new term that sparks a social movement in the lung cancer treatment journey – designed to elevate the patient voice and empower individuals to take an active role in shaping their treatment plan. By prioritizing shared decision-making between patients and healthcare professionals, this collaborative approach ensures that treatment choices are aligned to each patient’s goals, preferences and circumstances. This results in more informed decisions, greater patient satisfaction, and the best possible outcomes.
About Non-Small Cell Lung Cancer
Worldwide, lung cancer is one of the most common cancers, with NSCLC making up 80 to 85 percent of all lung cancer cases.[10], [11] The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.[12] Among the most common driver mutations in NSCLC are alterations in EGFR, which is a receptor tyrosine kinase controlling cell growth and division.[13] EGFR mutations are present in 10 to 15 percent of Western patients with NSCLC with adenocarcinoma histology and occur in 40 to 50 percent of Asian patients.[14], [15],[16],[17],[18],[19] EGFR ex19del or EGFR L858R mutations are the most common EGFR mutations.[20] The five-year survival rate for all people with advanced NSCLC and EGFR mutations treated with EGFR tyrosine kinase inhibitors (TKIs) is less than 20 percent. [21], [22] EGFR exon 20 insertion mutations are the third most prevalent activating EGFR mutation.[23] Patients with EGFR exon 20 insertion mutations have a real-world five-year overall survival (OS) of eight percent in the frontline setting, which is worse than patients with EGFR ex19del or L858R mutations, who have a real-world five-year OS of 19 percent.[24]By comparison, other common cancers, such as breast and prostate cancer have a 5-year real world OS of 90% and 97% respectively[25].
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
Learn more at 
https://www.jnj.com/ or at www.innovativemedicine.jnj.com. Follow us at @JNJInnovMed.
Media OutReach
Zuellig Pharma Acquires Cialis® (Tadalafil) from Lilly in three additional markets in Asia
Following the acquisition, Zuellig Pharma will now own the trademarks, marketing authorizations and license manufacturing know-how for Cialis®, a treatment for erectile dysfunction (ED) and benign prostatic hyperplasia (BPH), in 11 markets in Asia, with the expansion of its ownership into three additional markets beyond the original eight. Zuellig Pharma will also continue to promote and distribute the brand in these markets.
The expanded ownership of Cialis® will widen accessibility of the drug to a significant population of men in Asia who are affected by ED and BPH. The acquisition also aligns with Zuellig Pharma’s strategic priority of building a strong portfolio of owned prescription healthcare products as an integrated healthcare solutions company.
“Our acquisition of Cialis® in three additional markets builds on the strong foundation we established two years ago and highlights our proven success in scaling trusted brands effectively through our commercial capabilities and deep expertise. As we broaden our footprint, we remain focused on delivering sustainable growth and advancing our purpose of making in-demand healthcare solutions more accessible to communities in Asia,” said John Graham, CEO of Zuellig Pharma.
Hashtag: #ZuelligPharma #EliLillyandCompany #Cialis #MensHealth #Healthcare #Pharmaceuticals
https://www.zuelligpharma.com/
https://www.linkedin.com/company/zuellig-pharma
The issuer is solely responsible for the content of this announcement.
About Zuellig Pharma
Zuellig Pharma is a leading healthcare solutions company in Asia, and our purpose is to make healthcare more accessible to the communities we serve. We provide world-class distribution, commercialization, and clinical trial support services, underpinned by a strong culture of innovation to support the growing healthcare needs in this region. The company was founded a hundred years ago and has grown to become a multibillion-dollar business covering 18 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.
Media OutReach
Ingdan Powers Embodied AI with Humanoid-Style Brain-Cerebellum Chipset to Boost Robotics Ecosystem
2026 is widely regarded as a milestone year for humanoid robotics, in which humanoid robots transition from laboratory prototypes and demonstration performances to large‑scale mass production. At CES in January, NVIDIA announced the commercial launch of its physical‑AI core platform Jetson Thor. Tesla is scheduled to officially release the mass‑production engineering version of its Optimus (V3) humanoid robot by the end of March, with plans to initiate million‑unit‑level production lines by the end of 2026—an inflection point widely regarded as the “Model 3 moment” of the humanoid robotics industry. At the same time, Chinese robotics companies such as AGIBOT, Unitree, and Fourier Intelligence have already deployed products at scale in warehousing and logistics scenarios.
Against this backdrop, the upstream hardware focus of the humanoid robotics industry is increasingly converging on “Brain-Cerebellum” collaboration and low‑latency, multi‑joint real‑time control, which are essential to achieving coordinated, smooth, and human‑like robotic motion. During the CMG Spring Festival Gala, robots from multiple companies demonstrated complex coordinated movements and dexterous hand operations, further highlighting the value of this technical direction.
D‑Robotics, originating from the AIoT and robotics division of Horizon Robotics, focuses on edge‑side embodied intelligence solutions characterized by high computing power, integrated computation and control, and low latency. Leveraging its parent company’s long‑term experience in intelligent driving, D‑Robotics has established a precise position in humanoid robot “Brain-Cerebellum” coordination and real‑time joint control.
In November 2025, D‑Robotics unveiled its flagship robotics computing platform S600, with an official release planned for the end of the first quarter of 2026. The S600 platform features a highly integrated humanoid‑style “Brain-Cerebellum” chipset architecture. Its “Brain” configuration combines an 18‑core A78AE CPU with a proprietary Nash‑architecture BPU, delivering 560 TOPS (INT8) edge computing power and supporting efficient deployment of VLA, VLM, LLM, and locomotion models. Its “Cerebellum” configuration integrates a 6‑core R52+ MCU, providing high‑reliability, real‑time motion control.
By integrating CPU, BPU, and real‑time MCU capabilities into a single SoC, S600 enables a closed‑loop architecture encompassing perception, decision‑making, and real‑time action control. This design addresses a key industry challenge in which many edge AI processors lack embedded real‑time MCUs and rely on external controllers, resulting in excessive latency. The integrated MCU supports high‑frequency, high‑precision PWM signal generation based on FOC algorithms, enabling precise motor control and contributing to stable rhythm and natural gait.
The S600 platform has been adopted by multiple robotics companies such as Fourier Intelligence, Booster Robotics, X Square Robot, and ROBOTERA, supporting applications that require stable multi‑joint coordination and smooth motion performance.
Ingdan, Inc. (00400.HK) is a core supplier in the AI computing power supply chain and an application technology solutions provider covering both AI infrastructure and AI intelligent terminals. The Company represents a broad portfolio of international semiconductor manufacturers, including NVIDIA, Xilinx, Intel, AMD, and SanDisk, as well as numerous domestic chip vendors. It serves hundreds of robotics manufacturers and Tier‑1 customers and has formed a comprehensive embodied intelligence ecosystem.
D‑Robotics is a core product line Ingdan distributes . Building on D‑Robotics’ products and combined with its own technical services—such as multi‑sensor fusion development, real‑time closed‑loop tuning, Quantization‑Aware Training (QAT) support, simulation testing, and modular SOM customization—the Group has supported sophisticated customers including Galbot and ROBOTERA, continuously enriching the robotics industry ecosystem.
Looking ahead, Ingdan will continue to focus on the humanoid robotics sector. Leveraging an IC product matrix centered on NVIDIA Jetson and D‑Robotics platforms, the Company aims to further strengthen its AI intelligent terminal capabilities and continue supporting the iterative development of embodied intelligence products.
For investor and media enquiries
Please email to **@****an.com
Hashtag: #Ingdan #Chips #humanoid #D‑Robotics #NVIDIA #Tech
The issuer is solely responsible for the content of this announcement.
Ingdan, Inc.
Ingdan, Inc. (00400.HK) is a core supplier in the AI computing power supply chain and an application technology solutions provider covering both AI infrastructure and AI intelligent terminals. The Company represents a broad portfolio of international semiconductor manufacturers, including NVIDIA, Xilinx, Intel, AMD, and SanDisk, as well as numerous domestic chip vendors. It serves hundreds of robotics manufacturers and Tier‑1 customers and has formed a comprehensive embodied intelligence ecosystem.
Media OutReach
Snow, Ice, and Performance: 2026 Changan Global Testing Season Arrives in Europe with Back-to-Back Winter Events
- European dealers and journalists experienced the CHANGAN DEEPAL S05 AWD at 2026 Changan Global Testing Season this February.
- With intelligent AWD and advanced ADAS, the CHANGAN DEEPAL S05 AWD offered uncompromising safety and control on winter roads.
Saalfelden, Austria – Media OutReach Newswire – 12 March 2026 – Following extreme cold tests in Yakeshi, China, the 2026 Changan Global Testing Season made its European debut this February with the Changan Winter Experience in Courmayeur and the Winter Test Drives in Saalfelden. The all-electric CHANGAN DEEPAL S05 AWD was tested on snow and ice—familiar conditions for European drivers—offering dealers and journalists an immersive introduction to Changan’s electric mobility vision through dynamic drives.
Three-time Olympic gold medalist and Milano Cortina 2026 Ambassador Deborah Compagnoni joined the event in Courmayeur, testing the CHANGAN DEEPAL S05 AWD. Her career—defined by determination, control, and reliability—reflects Changan’s core values. “I felt that the principles of trajectory and speed in skiing apply to driving. With this model, you gain confidence on challenging terrain,” she said.
Snow-Validated Performance: The CHANGAN DEEPAL S05 AWD
Tested in Europe, the CHANGAN DEEPAL S05 AWD demonstrated controllable dynamics, reliable traction, and enhanced safety—highlighting its cutting-edge AWD and ADAS. The system adapts seamlessly: ECO/COMFORT modes prioritize RWD efficiency, while AWD will engage automatically when sensors detect slip, high torque demand, or extreme cold below -25°C. SPORT mode delivers permanent 50:50 torque for sharper response. SNOW mode maintains balanced torque with optimized slip control for confident driving on low-grip surfaces.
The intelligent AWD system delivers up to 320 kW power, 502 Nm torque, and 0–100 km/h acceleration in 5.5 seconds. It also improves hill climbing with a 40% gradient capability, ensures stability by actively balancing power to prevent skidding, and enables safer cornering at higher speeds through optimized grip and vehicle dynamics.
Changan Standard: Proven in the Alps, Bound for the World
Changan Standard is defined by a principle: forged in extremes, built for every day. From Yakeshi to the Alps, the test environments are selected to verify specific performance attributes—safety technologies, chassis response, all-wheel-drive calibration, and ADAS in low-grip scenarios. The objective of 2026 Global Testing Season is not to demonstrate extremes, but to confirm consistency: that the same level of safety, control, and stability demonstrated will be replicated in Mexico, Thailand, and Saudi Arabia.
Hashtag: #Changan
The issuer is solely responsible for the content of this announcement.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism10 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn